Evista raloxifene selective estrogen receptor modulator: Marketed to prevent osteoporosis

The company updated previously reported data on Evista's ability to prevent breast cancer in postmenopausal women with no history of breast cancer (see BioCentury, April 27). In 10,575 patients taking daily Evista therapy for a median follow-up of 40 months in 10 separate osteoporosis trials, overall breast cancer risk was reduced by 55 percent. The incidence of newly-diagnosed invasive breast cancer was reduced by 63 percent. Data were presented at the San Antonio Breast Cancer Symposium. ...